Top 10 rare disease pharma sees 10.4% rise in therapy start

A new case study from AllazoHealth demonstrates that a top 10 rare disease pharmaceutical company experienced a 10.4% increase in therapy initiation through AI-driven patient outreach and tailored, multi-channel communications.

The study highlights how AllazoHealth’s AI-enabled personalization strategy allowed the company to precisely time and tailor messages to patients, caregivers, infusion centers, and prescribers across various therapy types, including those with complex administration methods like clinic and home infusions, self-injections, and oral therapies. This targeted approach significantly boosted not only therapy starts but also adherence rates, with a 7.3% reduction in therapy discontinuation—a result that underscores the power of AI in patient support.

Prior to partnering with AllazoHealth, the pharmaceutical company relied on high-touch nurse support for outreach. However, such approaches, while effective, were both resource-intensive and challenging to scale, particularly for patients with rare diseases who often face additional complexities and specialized needs.

This new AI-powered system from AllazoHealth introduced a scalable solution that could customize messages based on each patient’s needs, including the timing and frequency of communication, the message content, and even the selection of channels like SMS, email, and live calls. AI allowed the company to better guide patients through critical stages of the therapy journey while simultaneously reducing operational costs and lifting patient outcomes.

The impact of AllazoHealth’s AI solution was far-reaching, involving about 10,000 patients across multiple therapeutic areas, and extended to caregivers and healthcare providers. Through daily updates, the AI system personalized and prioritized each communication attempt based on a variety of factors, including a patient’s past interaction patterns, likely response, and the optimal time of day to reach them. The result was a proactive support model that improved patients' onboarding experiences, maintained their engagement throughout treatment, and reduced the number of outreach calls required by nursing staff. Nurses reported greater overall satisfaction and felt they were better able to make a difference in patients’ lives, thanks to the enhanced efficiency and streamlined communication.

William Grambley, CEO of AllazoHealth, emphasized the importance of these results, noting that the technology not only exceeded the company’s initial goals but also demonstrated the potential of AI to achieve measurable improvements in health outcomes.

He said: “The outcomes of this case study went beyond our expectations,” he said, “helping us reduce non-clinical discontinuation rates while increasing therapy starts. AllazoHealth was able to predict individual patient behaviors and customize each communication with the ideal content and timing, resulting in a next-best-action model that leads to better outcomes and lower costs.”

For the pharmaceutical company, the technology provided a strategic advantage in a competitive landscape, demonstrating how AI can effectively reduce therapy discontinuation rates in areas of high patient need. In a healthcare setting where maintaining therapy adherence is challenging, AllazoHealth’s proactive, data-driven approach stands out as a solution capable of balancing cost and operational efficiency with superior patient support. HIPAA-compliant and built on Microsoft Azure, AllazoHealth’s platform is designed to maximize the efficiency of outreach for biopharma companies, enabling them to adapt to changing patient demands while maintaining security and scalability.

In a market where precision in patient support and adherence is paramount, AllazoHealth says its targeted approach has proven essential for biopharma companies facing complex patient journeys and cost challenges. With its HIPAA-compliant, HITRUST-certified platform, AllazoHealth continues to pioneer AI-driven solutions across therapeutic areas, maximizing engagement through Microsoft Azure’s secure and scalable infrastructure.